{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:40:05Z","timestamp":1792698005857,"version":"4.5.0"},"reference-count":61,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2019,2,12]]},"DOI":"10.3233\/jad-180766","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T21:33:04Z","timestamp":1548192784000},"page":"779-794","source":"Crossref","is-referenced-by-count":530,"title":["Treatment Combinations for Alzheimer\u2019s Disease: Current and Future Pharmacotherapy Options"],"prefix":"10.1177","volume":"67","author":[{"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tong","sequence":"additional","affiliation":[{"name":"Lundbeck, Deerfield, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, St Luke\u2019s Campus, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-180766_ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.3233\/JAD-180766_ref2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer\u2019s disease facts and figures","volume":"12","author":"Alzheimer\u2019s Association","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180766_ref4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of Alzheimer disease","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-180766_ref5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11910-014-0499-8","article-title":"Genetic heterogeneity in Alzheimer disease and implications for treatment strategies","volume":"14","author":"Ringman","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.3233\/JAD-180766_ref6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-180766_ref7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-180766_ref8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer\u2019s disease: therapeutic implications","volume":"8","author":"Mufson","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.3233\/JAD-180766_ref9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the beta secretase BACE1 for Alzheimer\u2019s disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-180766_ref10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-180766_ref17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1752-0509-6-52","article-title":"AlzPathway: a comprehensive map of signaling pathways of Alzheimer\u2019s disease","volume":"6","author":"Mizuno","year":"2012","journal-title":"BMC Syst Bio"},{"key":"10.3233\/JAD-180766_ref18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/00023210-200418130-00001","article-title":"Combination therapy in Alzheimer\u2019s disease: a review of current evidence","volume":"18","author":"Schmitt","year":"2004","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-180766_ref19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/1533317517698790","article-title":"Concordance of several subcellular interactions initiates Alzheimer\u2019s dementia: their reversal requires combination treatment","volume":"32","author":"Fessel","year":"2017","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.3233\/JAD-180766_ref20","first-page":"164","article-title":"Combination therapy of anti-tau and anti-amyloid drugs for disease modification in early-stage Alzheimer\u2019s disease: socio-economic considerations modeled on treatments for tuberculosis, HIV\/AIDS and breast cancer","volume":"3","author":"Tomaszewski","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-180766_ref21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1513\/pats.200504-037SR","article-title":"Pharmacologic principles for combination therapy","volume":"2","author":"Toews","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.3233\/JAD-180766_ref22","first-page":"1169","article-title":"Levodopa combined with peripheral decarboxylase inhibition in Parkinson\u2019s disease","volume":"106","author":"Barbeau","year":"1972","journal-title":"Can Med Assoc J"},{"key":"10.3233\/JAD-180766_ref23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","article-title":"Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect","volume":"68","author":"Pioro","year":"2010","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-180766_ref24","first-page":"109","article-title":"Defining disease modifying therapy for Alzheimer\u2019s disease","volume":"4","author":"Cummings.","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-180766_ref25","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1523\/JNEUROSCI.5077-10.2011","article-title":"Robust amyloid clearance in a mouse model of Alzheimer\u2019s disease provides novel insights into the mechanism of amyloid-beta immunotherapy","volume":"31","author":"Wang","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-180766_ref26","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/archneurol.2011.183","article-title":"Evidence for ordering of Alzheimer disease biomarkers","volume":"68","author":"Jack","year":"2011","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-180766_ref27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease","volume":"61","author":"Parkinson Study Group","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-180766_ref28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1015131516649","article-title":"Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]","volume":"21","author":"Youdim","year":"2001","journal-title":"Cell Mol Neurobiol"},{"key":"10.3233\/JAD-180766_ref30","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer\u2019s disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-180766_ref31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-180766_ref33","doi-asserted-by":"crossref","first-page":"a006387","DOI":"10.1101\/cshperspect.a006387","article-title":"Treatment strategies targeting amyloid beta-protein","volume":"2","author":"Schenk","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JAD-180766_ref34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny.","year":"2016","journal-title":"Nature"},{"key":"10.3233\/JAD-180766_ref35","first-page":"1359","article-title":"Profile of gantenerumab and its potential in the treatment of Alzheimer\u2019s disease","volume":"7","author":"Novakovic","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.3233\/JAD-180766_ref36","doi-asserted-by":"crossref","first-page":"P610","DOI":"10.1016\/j.jalz.2016.06.1210","article-title":"Exploratory analyses of cognitive effects of crenezumab in a mild Alzheimer\u2019s disease subpopulation of a randomized, double-blind, placebo controlled, parallel-group phase 2 study (ABBY)","volume":"12","author":"Mackey","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180766_ref37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-180766_ref39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-180766_ref40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180766_ref42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.3233\/JAD-180766_ref43","first-page":"3245935","article-title":"Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease","volume":"2016","author":"Panza","year":"2016","journal-title":"Biomed Res In"},{"key":"10.3233\/JAD-180766_ref44","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JAD-180766_ref45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: a randomised, placebo-controlled phase 2 trial","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-180766_ref46","doi-asserted-by":"crossref","first-page":"781","DOI":"10.17219\/acem\/61914","article-title":"The role of mast cells in Alzheimer\u2019s disease","volume":"25","author":"Shaik-Dasthagirisaheb","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"10.3233\/JAD-180766_ref47","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1074\/jbc.M114.586602","article-title":"A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease","volume":"290","author":"Hori","year":"2015","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-180766_ref48","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.febslet.2008.04.057","article-title":"The antioxidant properties of serum albumin","volume":"582","author":"Roche","year":"2008","journal-title":"FEBS Lett"},{"key":"10.3233\/JAD-180766_ref49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nrl.2014.02.003","article-title":"Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: rationale and treatment aroach of the AMBAR (Alzheimer Management By Albumin Replacement) study","volume":"31","author":"Boada","year":"2016","journal-title":"Neurologia"},{"key":"10.3233\/JAD-180766_ref50","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4155\/fmc.12.51","article-title":"Is RAGE still a therapeutic target for Alzheimer\u2019s disease?","volume":"4","author":"Deane","year":"2012","journal-title":"Future Med Chem"},{"key":"10.3233\/JAD-180766_ref52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.9740\/mhc.n204371","article-title":"Antipsychotic use in elderly patients with dementia: efficacy and safety concerns","volume":"4","author":"Marvanova","year":"2014","journal-title":"Mental Health Clin"},{"key":"10.3233\/JAD-180766_ref53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1533317511402051","article-title":"Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence","volume":"26","author":"Henry","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.3233\/JAD-180766_ref54","first-page":"CD003476","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer\u2019s disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-180766_ref55","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease","volume":"355","author":"Schneider","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-180766_ref56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0269881105056524","article-title":"Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia","volume":"19","author":"Layton","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.3233\/JAD-180766_ref57","unstructured":"Risperidal\u00ae (2009) (risperidone). Full Prescribing Information, Ortho-McNeil-Janssen Pharmaceuticals Inc, Titusville, NJ."},{"key":"10.3233\/JAD-180766_ref58","unstructured":"ZYPREXA (2018) (olanzapine). Full Prescribing Information, Eli Lilly and Company, Indianapolis, IN."},{"key":"10.3233\/JAD-180766_ref59","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia","volume":"146","author":"Gill","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-180766_ref60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","article-title":"Second generation antipsychotics in the treatment of major depressive disorder: an update","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam Med J"},{"key":"10.3233\/JAD-180766_ref63","first-page":"S6","article-title":"Effect of cholinesterase inhibitors on behavior","volume":"29","author":"Cummings","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-180766_ref64","doi-asserted-by":"crossref","first-page":"e35185","DOI":"10.1371\/journal.pone.0035185","article-title":"Efficacy of memantine for agitation in Alzheimer\u2019s dementia: a randomised double-blind placebo controlled trial","volume":"7","author":"Fox","year":"2012","journal-title":"PLoS One"},{"key":"10.3233\/JAD-180766_ref65","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","article-title":"5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer\u2019s disease","volume":"5","author":"Upton","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-180766_ref66","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer\u2019s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"13","author":"Wilkinson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-180766_ref67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials","volume":"319","author":"Atri","year":"2018","journal-title":"JAMA"},{"key":"10.3233\/JAD-180766_ref68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trci.2015.04.001","article-title":"Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer\u2019s disease","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-180766_ref71","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","article-title":"Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B","volume":"132","author":"Youdim","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.3233\/JAD-180766_ref72","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jnr.20350","article-title":"Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition","volume":"79","author":"Youdim","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-180766_ref74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jalz.2016.02.007","article-title":"Challenges, solutions, and recommendations for Alzheimer\u2019s disease combination therapy","volume":"12","author":"Hendrix","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180766_ref75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures","volume":"3","author":"Evans","year":"2010","journal-title":"J Exp Stroke Transl Med"},{"key":"10.3233\/JAD-180766_ref76","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jamaneurol.2017.1528","article-title":"I-SPY 2 breast cancer trial as a model for innovation in Alzheimer disease therapies","volume":"74","author":"Messmer","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-180766_ref80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","article-title":"Development of interventions for the secondary prevention of Alzheimer\u2019s dementia: the European Prevention of Alzheimer\u2019s Dementia (EPAD) project","volume":"3","author":"Ritchie","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.3233\/JAD-180766_ref83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd.2017.66","article-title":"Combination products: modernizing the regulatory paradigm","volume":"16","author":"Hunter","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-180766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:49Z","timestamp":1777370929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-180766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":61,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-180766","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,12]]}}}